Add-on to 1-3 oral anti-hyperglycemic agents (metformin, sulfonylurea, or SGLT-2 inhibitor) SURPASS-4 (NCT03730662) was a 104-week open-label trial (52-week primary endpoint) that randomized 2002 adult patients with type 2 diabetes mellitus with increased cardiovascular risk to subcutaneous MOUNJARO 5 mg, MOUNJARO 10 mg, MOUNJARO 15 mg once weekly, or insulin glargine 100 units/mL once daily (1:1:1:3 ratio) on a background of metformin (95%) and/or sulfonylureas (54%) and/or SGLT2 inhibitors (25%)
Patients with surgical scars or acne marks often report faster fading and a softer scar texture
By balancing the inflammatory response with peptides, peptide therapy can help balance the immune response in your body
Certain groups, including vegetarians, vegans, and older adults, are at higher risk for B12 deficiency and should consider supplements or fortified foods
Available as standalone weekly injections or combined with Lipo-Slim Shots
Doing the division wrong
